ADHD Medication Crisis: Nationwide Shortage Triggers Price Hike

ADHD Medication Crisis: Nationwide Shortage Triggers Price Hike

A nationwide shortage of drugs used to treat attention deficit hyperactivity disorder (ADHD) has led to a price surge affecting many patients across the country. According to a recent analysis by USA Today, the prices for common ADHD medications have risen significantly, with some doubling or even tripling in the past year, outpacing inflation rates.

The scarcity of these essential medications, particularly Adderall, has forced patients to seek costly brand-name alternatives as generic versions become harder to find. The Food and Drug Administration (FDA) cited ‘intermittent manufacturing delays’ as the cause of the Adderall shortage announced in October 2022, disrupting the supply chain and contributing to the price hike. Various studies indicate that an estimated 6 million children and 11 million adults suffer from ADHD, relying on such medications to manage symptoms and improve focus.

In response to the shortage, patients like a Delaware mother have shared their struggles. Facing the unavailability of Adderall, her daughter’s prescribed medication, they had to switch to Vyvanse, a more expensive alternative. Consequently, their monthly expenses soared from under $20 to a staggering $300 post-insurance coverage. The price tag without insurance further demonstrates the financial burden, amounting to approximately $1,306 for a 100-capsule supply of Vyvanse, as reported by

As patients navigate the shortage and escalating prices, the impact extends to education and well-being. While some patients opt for cheaper generic options, the costs remain significant. GoodRx notes that generic Vyvanse is priced at $100, whereas brand-name Vyvanse starts at $369, slightly surpassing the rate of brand-name Adderall. This financial strain has left families like the Delaware mother’s in a precarious situation, where prioritizing their daughter’s health and academic success comes at a steep cost.

Despite efforts to address the shortage at a production level, challenges persist. The Drug Enforcement Administration (DEA) has been modifying quota restrictions to boost production of ADHD stimulants, aiming to alleviate the scarcity. However, the impact on patients remains palpable, with some facing what the mother described as an ‘additional ADHD tax.’ This tax encompasses not only the financial burden of increased medication prices but also the emotional toll of traveling long distances to find available drugs.

In light of these challenges, voices within the ADHD community emphasize the importance of recognizing the severity of the issue. Discussing the impact on quality of life, patients and advocates stress that ADHD is a genuine disability that significantly affects daily functioning. As stakeholders work towards mitigating the effects of the shortage, the focus remains on ensuring access to essential medications for all individuals in need of ADHD treatment.


No responses yet

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Latest Comments

    No comments to show.